This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Blood and Marrow Transplant Clinical Research Network

This study has been completed.
Blood and Marrow Transplant Clinical Trials Network
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: September 7, 2001
Last updated: February 17, 2016
Last verified: July 2006
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.

Condition Intervention
Bone Marrow Transplantation Blood Disease Hematopoietic Stem Cell Transplantation Leukemia Multiple Myeloma Myelodysplastic Syndromes Graft vs Host Disease Drug: fluconazole Drug: voriconazole Procedure: bone marrow transplant Drug: thalidomide Drug: dexamethasone

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Blood and Marrow Transplant Clinical Research Network

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 2001
Study Completion Date: August 2006
  Show Detailed Description


Ages Eligible for Study:   2 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria for entry into a study varies by protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00023530

United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
University of California at San Diego
La Jolla, California, United States, 92093
Stanford University
Palo Alto, California, United States, 94305
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Michigan
University of Michigan at Ann Arbor
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
University of Minnesota Twin Cities
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New York
Sloan-Kettering Institute for Cancer Research
New York, New York, United States, 10021
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
OverallOfficial: Joseph Antin Dana-Farber Cancer Institute
OverallOfficial: Frederick Appelbaum Fred Hutchinson Cancer Research Center
OverallOfficial: Edward Ball University of California, San Diego
OverallOfficial: James Ferrara University of Michigan at Ann Arbor
OverallOfficial: Stephen Forman City of Hope National Medical Center
OverallOfficial: Alan Gamis Children's Mercy Hospital
OverallOfficial: Sergio Giralt M.D. Anderson Cancer Center
OverallOfficial: Mary Horowitz Medical College of Wisconsin
OverallOfficial: Richard Jones Johns Hopkins University
OverallOfficial: Joanne Kurtzberg Duke University
OverallOfficial: Gina Laport Stanford University
OverallOfficial: Hillard Lazarus Case Western Reserve University
OverallOfficial: Richard O'Reilly Sloan-Kettering Institute for Cancer Research
OverallOfficial: Edward Stadtmauer University of Pennsylvania
OverallOfficial: Julie Vose University of Nebraska
OverallOfficial: Daniel Weisdorf University of Minnesota, MN
OverallOfficial: John Wingard University of Florida
  More Information

Publications: Identifier: NCT00023530     History of Changes
Other Study ID Numbers: 139
U01HL069301 ( U.S. NIH Grant/Contract )
Study First Received: September 7, 2001
Last Updated: February 17, 2016

Additional relevant MeSH terms:
Multiple Myeloma
Myelodysplastic Syndromes
Graft vs Host Disease
Hematologic Diseases
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Precancerous Conditions
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids processed this record on September 21, 2017